

# Ralph W Kuncel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10913382/publications.pdf>

Version: 2024-02-01

49  
papers

9,896  
citations

147566

31  
h-index

197535

49  
g-index

52  
all docs

52  
docs citations

52  
times ranked

6766  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thymectomy in Pemphigus Foliaceus: A Thirty-Year Observation. <i>Journal of Medical Cases</i> , 2021, 12, 41-44.	0.4	0
2	Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 235-245.	1.1	20
3	Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 538-546.	1.1	17
4	Associations between cancer and Parkinson's disease in U.S. elderly adults. <i>International Journal of Epidemiology</i> , 2016, 45, 741-751.	0.9	25
5	Associations between cancer and Alzheimer's disease in a U.S. Medicare population. <i>Cancer Medicine</i> , 2016, 5, 2965-2976.	1.3	64
6	Calbindin $\text{D}_{28K}$ is increased in the ventral horn of spinal cord by neuroprotective factors for motor neurons. <i>Journal of Neuroscience Research</i> , 2015, 93, 1184-1191.	1.3	8
7	The risk of amyotrophic lateral sclerosis after cancer in U.S. elderly adults: A population-based prospective study. <i>International Journal of Cancer</i> , 2014, 135, 1745-1750.	2.3	30
8	Toxic Myopathies. , 2014, , 1403-1426.		0
9	The association between cancer and amyotrophic lateral sclerosis. <i>Cancer Causes and Control</i> , 2013, 24, 55-60.	0.8	43
10	Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 246-251.	1.1	38
11	Comment on "Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: Pooled results from 5 cohort studies": <i>Annals of Neurology</i> , 2013, 74, 307-307.	2.8	1
12	Agents and mechanisms of toxic myopathy. <i>Current Opinion in Neurology</i> , 2009, 22, 506-515.	1.8	46
13	Amyotrophic Lateral Sclerosis Mortality in 1.9 Million US Cancer Survivors. <i>Neuroepidemiology</i> , 2005, 25, 176-180.	1.1	40
14	Multifocal motor neuropathy: Response to human immune globulin. <i>Annals of Neurology</i> , 2004, 33, 237-242.	2.8	193
15	Exocytotic "constipation" is a mechanism of tubulin/lysosomal interaction in colchicine myopathy. <i>Experimental Cell Research</i> , 2003, 285, 196-207.	1.2	31
16	Identification of the Neuroprotective Molecular Region of Pigment Epithelium-Derived Factor and Its Binding Sites on Motor Neurons. <i>Journal of Neuroscience</i> , 2002, 22, 9378-9386.	1.7	102
17	Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. <i>Journal of Neurochemistry</i> , 2002, 81, 178-184.	2.1	56
18	Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. <i>NeuroReport</i> , 2001, 12, 2531-2535.	0.6	38

#	ARTICLE	IF	CITATIONS
19	Neuroprotective Utility and Neurotrophic Action of Neurturin in Postnatal Motor Neurons: Comparison with GDNF and Persephin. <i>Molecular and Cellular Neurosciences</i> , 1999, 13, 326-336.	1.0	50
20	Preclinical Testing of Neuroprotective Neurotrophic Factors in a Model of Chronic Motor Neuron Degeneration. <i>Neurobiology of Disease</i> , 1999, 6, 335-346.	2.1	100
21	Pigment Epithelium-derived Factor (PEDF) Protects Motor Neurons from Chronic Glutamate-mediated Neurodegeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 719-728.	0.9	154
22	AGE-RELATED BIOLOGY AND DISEASES OF MUSCLE AND NERVE. <i>Neurologic Clinics</i> , 1998, 16, 659-669.	0.8	22
23	Myology of the Pharyngoesophageal Segment: Gross Anatomic and Histologic Characteristics. <i>Laryngoscope</i> , 1996, 106, 713-720.	1.1	18
24	Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of Glutamate. <i>Neuron</i> , 1996, 16, 675-686.	3.8	2,332
25	Sensory nerve pathology in multifocal motor neuropathy. <i>Annals of Neurology</i> , 1996, 39, 319-325.	2.8	89
26	A $\gamma$ -subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome. <i>Annals of Neurology</i> , 1996, 39, 712-723.	2.8	112
27	Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1995, 38, 73-84.	2.8	1,356
28	Neuroprotective Strategies in a Model of Chronic Glutamate-Mediated Motor Neuron Toxicity. <i>Journal of Neurochemistry</i> , 1995, 65, 643-651.	2.1	184
29	Multifocal motor neuropathy: Electrodiagnostic features. <i>Muscle and Nerve</i> , 1994, 17, 198-205.	1.0	126
30	Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. <i>Annals of Neurology</i> , 1994, 35, 142-150.	2.8	95
31	Localization of neuronal and glial glutamate transporters. <i>Neuron</i> , 1994, 13, 713-725.	3.8	1,575
32	A Novel Therapy for Myasthenia Gravis by Reducing the Endocytosis of Acetylcholine Receptors. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 298-302.	1.8	6
33	Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis. <i>New England Journal of Medicine</i> , 1992, 326, 1464-1468.	13.9	1,125
34	Novel mutations in families with unusual and variable disorders of the skeletal muscle sodium channel. <i>Nature Genetics</i> , 1992, 2, 148-152.	9.4	140
35	Nerve conduction studies in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 1992, 15, 1111-1115.	1.0	97
36	Inter- and intra-examiner reliability of nerve conduction measurements in normal subjects. <i>Annals of Neurology</i> , 1991, 30, 841-843.	2.8	101

#	ARTICLE	IF	CITATIONS
37	Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1990, 28, 18-25.	2.8	604
38	Paramyotonia congenita or hyperkalemic periodic paralysis? Clinical and electrophysiological features of each entity in one family. <i>Muscle and Nerve</i> , 1990, 13, 21-26.	1.0	55
39	Electrodiagnosis of human colchicine myoneuropathy. <i>Muscle and Nerve</i> , 1989, 12, 360-364.	1.0	38
40	Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1989, 25, 98-102.	2.8	97
41	Amyotrophic lateral sclerosis: An unconventional autoimmune disease?. <i>Annals of Neurology</i> , 1989, 26, 269-274.	2.8	76
42	Assessment of thoracic paraspinal muscles in the diagnosis of ALS. <i>Muscle and Nerve</i> , 1988, 11, 484-492.	1.0	102
43	Toxic Myopathies. <i>Neurologic Clinics</i> , 1988, 6, 593-619.	0.8	25
44	Colchicine Myopathy and Neuropathy. <i>New England Journal of Medicine</i> , 1987, 316, 1562-1568.	13.9	394
45	The pathophysiology of penicillamine-induced myasthenia gravis. <i>Annals of Neurology</i> , 1986, 20, 740-744.	2.8	27
46	Phospholipid methylation in skeletal muscle membranes. <i>Muscle and Nerve</i> , 1985, 8, 426-434.	1.0	6
47	Beta adrenergic-mediated myofibrillar disruption and enzyme efflux in an experimental myopathy related to isometric muscle activity. <i>Experimental and Molecular Pathology</i> , 1979, 31, 113-123.	0.9	5
48	Role of the adrenal in an experimental myopathy. <i>Experimental Neurology</i> , 1977, 57, 322-330.	2.0	4
49	Pathologic effect of phencyclidine and restraint on rat skeletal muscle structure: Prevention by prior denervation. <i>Experimental Neurology</i> , 1974, 45, 387-402.	2.0	18